Spray-freeze drying

01Overview and value chain#

Markers EC: EU GMP Annex 1 sterile-freeze-dry requirements + FDA/EMA/NMPA lyophilized-product stability dossiers | OECD: Industrial biotechnology | Regulator: FDA (USA), EMA (EU), NMPA (China)

Spray-freeze drying is the low-temperature dehydration route for products that collapse, denature or lose activity if they ever get warm and wet at the same time: the liquid feed is atomized into a cryogenic medium where droplets freeze instantly into a porous matrix, and vacuum then removes the ice by sublimation — solid to vapor, never through a liquid phase. The distinction from conventional batch lyophilization is geometry and continuity: tray freeze-driers freeze a loaded vial or bulk layer and wait days for sublimation to crawl down a product depth, while spray-freeze variants freeze small droplets whose entire depth freezes in seconds, promising shorter cycles and continuous operation at the price of a powder-handling step. The corpus’s operating evidence comes from the equipment layer that owns this niche — every vendor tabled here sells the freeze-dryer line into which spray-freeze configurations integrate. Martin Christ has delivered its 30,000th freeze dryer (an Epsilon 2-10D LyoLift to Coriolis Pharma in April 2026) with roughly 60 employees and estimated revenue around €15 million; SP Scientific’s VirTis line runs the pharma pilot workhorse under LyoLogic HMI with 21 CFR Part 11-ready compliance; Syntegon carries end-to-end fill-finish and freeze-dry lines at €1.75 billion fiscal-2025 revenue; Tofflon holds roughly 60% of China’s mid-to-high-end lyophilizer market; and Telstar’s LyoBeta research units span −83 to 60 °C with 30 kg condensers.

Key directions of spray-freeze drying:

1. Continuous freeze-drying (SFD Configuration): droplet freezing followed by vacuum sublimation replaces tray residence time — the cycle-compression direction inside the vendor line set.
2. Pilot-to-production lyophilization (Scale-up Chain): the VirTis Genesis 30 and Ultra Prime 30 pilot units and Martin Christ’s Epsilon class carry process development from lab to GMP suites.
3. Biopharma capacity build-out (Lyophilizer Capacity): Syntegon doubled global fill-finish and freeze-dry capacity after its US$445 million acquisition by ATS Automation; Tofflon builds 10–15,000 L stainless bioreactor lines alongside its ~60% domestic lyophilizer share.
4. Controlled-temperature research units (−83 to 60 °C Class): Telstar’s LyoBeta research-and-scale-up dryers with 30 kg condensers and 0.9 m² shelf area carry formulation science.

Sectoral value chain#

[liquid feed] ──> [atomization into cryogen] ──> [frozen droplet matrix]
                                                          │
                                             (sublimation under vacuum)
                                                          ▼
[powder product] <── [secondary drying] <── [primary drying]

Value chain levels#

Cross-cutting technologies of the sector:

• Vacuum and condenser engineering (Ice-Load Management): condenser capacity — Telstar’s 30 kg class — bounds batch size.
• HMI and batch records (21 CFR Part 11 Controls): LyoLogic-class control systems keep drying recipes auditable.
• Aseptic powder handling (Inert Collection): closed, inert-atmosphere powder paths that keep a sterile powder sterile.

02US#

The US hosts the pilot-scale equipment lineage and the compliance regime that defines lyophilized-product release.

VirTis pilot workhorse, Part 11 controls, ATS acquisition scale#

• SP Scientific: the VirTis Genesis 30 and Ultra Prime 30 pilot freeze dryers run LyoLogic HMI in 21 CFR Part 11-compliance-ready versions; the company was acquired by ATS Automation Tooling Systems for US$445 million and doubled global manufacturing capacity for fill-finish and freeze-dry equipment.
• Compliance envelope: Part 11-ready batch records are the US entry ticket for drying equipment.
• Research-to-GMP chain: pilot units feed the GMP suites where stability dossiers are built.

03CN#

China is the volume lyophilizer market, and Tofflon is its domestic champion — the corpus’s ledger evidence places roughly 60% of the mid-to-high-end domestic market with one vendor.

Tofflon’s domestic share, Shanghai manufacturing base, adjacent bioreactor lines#

• Tofflon (Shanghai, founded 1993): roughly 60% of China’s mid-to-high-end lyophilizer market, backed by $8 million of venture and corporate funding, now extending into 10–15,000 L stainless bioreactors with PAT systems.
• Equipment localization: Chinese biopharma capacity build-out sources freeze-dry equipment domestically at scale.
• Export pressure: the same capacity push pushes Chinese freeze-dry lines into export markets.

04EU#

Europe owns the freeze-drying equipment tradition — German engineering depth with Spanish research units — and the GMP framework that formats every drying recipe.

Martin Christ’s 30,000th dryer, Syntegon’s line integration, Telstar’s research class#

• Martin Christ (Germany): 75-plus years in the field; the 30,000th freeze dryer — an Epsilon 2-10D LyoLift — delivered to Coriolis Pharma in April 2026; roughly 60 employees and estimated revenue around €15 million, with public funding of €194,414 for the RUENNA project.
• Syntegon (Germany): formerly Bosch Packaging Technology; €1.75 billion fiscal-2025 revenue, more than 7,000 employees across 49 locations in over 20 countries — end-to-end formulation-to-freeze-dry line integration.
• Telstar (Spain): the LyoBeta research-and-scale-up class (−83 to 60 °C, 30 kg condenser, up to 0.9 m² shelf) with ISO 9001:2015, ISO 14001:2015 and ASME certification across Spanish and Chinese sites.

05Leading companies and research institutes#

06Tech stack and innovations#

The stack is vacuum physics plus compliance engineering; the innovations are in condensers, controls and the powder path.

1. Cryogenic droplet freezing (SFD Front End):
   • atomized droplets freeze in seconds into a porous matrix whose entire depth sublimes — no tray-depth diffusion limit.
   • case: the niche integrates into vendor freeze-dryer lines from SP Scientific’s VirTis pilot class upward.
2. Condenser and vacuum trains (Ice-Load Class):
   • condenser capacity bounds the batch — Telstar’s LyoBeta carries a 30 kg condenser against a 0.9 m² shelf.
   • case: Martin Christ’s LyoLift delivery class for GMP process suites.
3. Controlled drying recipes (Part 11 HMI):
   • LyoLogic-class HMIs run shelf-temperature and chamber-pressure recipes as auditable batch records.
   • case: SP Scientific’s 21 CFR Part 11-compliance-ready LyoLogic versions across the VirTis Genesis 30 and Ultra Prime 30.

07Value chains and production pipelines#

Industrial pipeline of a sterile freeze-dry suite (EU GMP Annex 1 regime)#

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Feed formulation       │ ───> │ 2. Atomization, freezing  │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Secondary drying       │ <─── │ 3. Primary sublimation    │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Powder handling        │ ───> │ 6. Compliance and release │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Feed formulation

Cryoprotectants and solids loading are fixed so droplets freeze into a matrix that survives sublimation without collapse.

Stage 2: Atomization and freezing

The feed is atomized into a cryogenic medium; droplets freeze through in seconds, fixing a porous structure no tray route can copy.

Stage 3: Primary drying

Vacuum pulls ice directly to vapor; shelf and chamber-pressure recipes keep the product below its collapse temperature.

Stage 4: Secondary drying

Bound water is desorbed to the residual-moisture specification that the stability dossier was filed against.

Stage 5: Powder handling

Dried powder is collected and dosed under inert atmosphere — the step that decides whether a sterile powder stays sterile.

Stage 6: Compliance and release

Moisture, potency and stability data close the GMP batch record under EU Annex 1 and FDA/NMPA expectations.